R
R. David Anderson
Researcher at University of Florida
Publications - 124
Citations - 5682
R. David Anderson is an academic researcher from University of Florida. The author has contributed to research in topics: Coronary artery disease & Myocardial infarction. The author has an hindex of 28, co-authored 109 publications receiving 4954 citations. Previous affiliations of R. David Anderson include Duke University & Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study.
Carl J. Pepine,R. David Anderson,Barry L. Sharaf,Steven E. Reis,Karen M. Smith,Eileen M. Handberg,B. Delia Johnson,George Sopko,C. Noel Bairey Merz +8 more
TL;DR: In this article, the authors investigated whether coronary microvascular dysfunction predicts major adverse outcomes during follow-up among women with signs and symptoms of ischemia, and they found significant associations between CFR and major adverse events (death, nonfatal myocardial infarction, non-fatal stroke, or hospital stay for heart failure).
Journal ArticleDOI
Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
Robert J. Lederman,Farrell O. Mendelsohn,R. David Anderson,Jorge F Saucedo,Alan N. Tenaglia,James B. Hermiller,William B. Hillegass,Krishna J. Rocha-Singh,Thomas Moon,M.J. Whitehouse,Brian H. Annex +10 more
TL;DR: Intra-arterial rFGF-2 resulted in a significant increase in peak walking time at 90 days; repeat infusion at 30 days was no better than one infusion and the findings of TRAFFIC provide evidence of clinical therapeutic angiogenesis by intra-arteria infusion of an angiogenic protein.
Journal ArticleDOI
Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart Failure: The FOCUS-CCTRN Trial
Emerson C. Perin,James T. Willerson,Carl J. Pepine,Timothy D. Henry,Stephen G. Ellis,David Zhao,Guilherme V. Silva,Dejian Lai,James D. Thomas,Marvin W. Kronenberg,A. Daniel Martin,R. David Anderson,Jay H. Traverse,Marc S. Penn,Saif Anwaruddin,Antonis K. Hatzopoulos,Adrian P. Gee,Doris A. Taylor,Christopher R. Cogle,Deirdre Smith,Lynette Westbrook,James Chen,Eileen M. Handberg,Rachel E. Olson,Carrie Geither,Sherry Bowman,Judy Francescon,Sarah Baraniuk,Linda B. Piller,Lara M. Simpson,Catalin Loghin,David Aguilar,Sara Richman,Claudia Zierold,Judy Bettencourt,Shelly L. Sayre,Rachel W. Vojvodic,Sonia I. Skarlatos,David Gordon,Ray F. Ebert,Minjung Kwak,Lemuel A. Moyé,Robert D. Simari +42 more
TL;DR: Among patients with chronic ischemic heart failure, transendocardial injection of autologous BMCs compared with placebo did not improve LVESV, maximal oxygen consumption, or reversibility on SPECT.
Journal ArticleDOI
Effect of the Use and Timing of Bone Marrow Mononuclear Cell Delivery on Left Ventricular Function After Acute Myocardial Infarction: The TIME Randomized Trial
Jay H. Traverse,Timothy D. Henry,Carl J. Pepine,James T. Willerson,David Zhao,Stephen G. Ellis,John R. Forder,R. David Anderson,Antonis K. Hatzopoulos,Marc S. Penn,Emerson C. Perin,Jeffrey W. Chambers,Kenneth W. Baran,Ganesh Raveendran,Charles R. Lambert,Amir Lerman,Daniel I. Simon,Douglas E. Vaughan,Dejian Lai,Adrian P. Gee,Doris A. Taylor,Christopher R. Cogle,James D. Thomas,Rachel E. Olson,Sherry Bowman,Judy Francescon,Carrie Geither,Eileen M. Handberg,Casey Kappenman,Lynette Westbrook,Linda B. Piller,Lara M. Simpson,Sarah Baraniuk,Catalin Loghin,David Aguilar,Sara Richman,Claudia Zierold,Daniel B. Spoon,Judy Bettencourt,Shelly L. Sayre,Rachel W. Vojvodic,Sonia I. Skarlatos,David Gordon,Ray F. Ebert,Minjung Kwak,Lemuel A. Moyé,Robert D. Simari +46 more
TL;DR: Among patients with STEMI treated with primary PCI, the administration of intracoronary BMCs at either 3 days or 7 days after the event had no significant effect on recovery of global or regional left ventricular function compared with placebo.
Effect of the Use and Timing of Bone Marrow Mononuclear Cell Delivery on Left Ventricular Function After Acute Myocardial Infarction
Jay H. Traverse,Timothy D. Henry,Carl J. Pepine,David Zhao,Stephen G. Ellis,John R. Forder,R. David Anderson,Antonis K. Hatzopoulos,Emerson C. Perin,Jeffrey W. Chambers,Ganesh Raveendran,Charles R. Lambert,Daniel I. Simon,Douglas E. Vaughan,Dejian Lai,Adrian P. Gee,Christopher R. Cogle,James D. Thomas,Rachel E. Olson,Sherry Bowman,Carrie Geither,Eileen M. Handberg,Lynette Westbrook,Linda B. Piller,Sarah Baraniuk,Catalin Loghin,David Aguilar,Sara Richman,Claudia Zierold,Daniel B. Spoon,Judy Bettencourt,Shelly L. Sayre,Sonia I. Skarlatos,David Gordon,Ray F. Ebert,Minjung Kwak,Robert D. Simari +36 more
TL;DR: In this paper, the authors showed that the administration of intracoronary BMCs at either 3 days or 7 days after the event had no significant effect on recovery of global or regional left ventricular function compared with placebo.